CADUS PHARMACEUTICAL CORP
10-Q, EX-27, 2000-11-14
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: CADUS PHARMACEUTICAL CORP, 10-Q, 2000-11-14
Next: MICRO COMPONENT TECHNOLOGY INC, 10-Q, 2000-11-14



<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial
information extracted from the Balance Sheet, and
Income Statement and is qualified in its entirety
by reference to such financial statements.
</LEGEND>
<MULTIPLIER>                               1

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                       DEC-31-2000
<PERIOD-END>                            SEP-30-2000
<CASH>                                   24,844,573
<SECURITIES>                                      0
<RECEIVABLES>                                     0
<ALLOWANCES>                                      0
<INVENTORY>                                       0
<CURRENT-ASSETS>                         25,020,887
<PP&E>                                            0
<DEPRECIATION>                                    0
<TOTAL-ASSETS>                           26,292,700
<CURRENT-LIABILITIES>                     1,068,256
<BONDS>                                           0
                             0
                                       0
<COMMON>                                    132,857
<OTHER-SE>                               25,091,587
<TOTAL-LIABILITY-AND-EQUITY>             26,292,700
<SALES>                                           0
<TOTAL-REVENUES>                            723,470
<CGS>                                             0
<TOTAL-COSTS>                                     0
<OTHER-EXPENSES>                          1,451,793
<LOSS-PROVISION>                                  0
<INTEREST-EXPENSE>                                0
<INCOME-PRETAX>                          17,587,245
<INCOME-TAX>                                (16,181)
<INCOME-CONTINUING>                               0
<DISCONTINUED>                                    0
<EXTRAORDINARY>                                   0
<CHANGES>                                         0
<NET-INCOME>                             17,603,426
<EPS-BASIC>                                    1.34
<EPS-DILUTED>                                  1.34



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission